BG
LABU icon

Bellevue Group’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Bellevue Group’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-750
Closed -$338K – 216
2020
Q1 		$338K Buy
+750
New +$682K 0.01% 194
2018
Q1 		– Sell
-1,920
Closed -$2.99M – 129
2017
Q4 		$2.99M Buy
+1,920
New +$2.94M 0.31% 65
2017
Q1 		– Sell
-1,259
Closed -$788K – 134
2016
Q4 		$788K Hold
1,259
– – 0.16% 96
2016
Q3 		$1.23M Sell
1,259
-1,500
-54% -$1.24M 0.22% 90
2016
Q2 		$1.56M Buy
2,759
+1,750
+173% +$1.1M 0.29% 82
2016
Q1 		$553K Buy
+1,009
New +$638K 0.1% 109

Other funds holding LABU

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HIS
Harvest Investment Services Oakbrook Terrace, Illinois $547M AUM 64.58% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HJMC
Hellman Jordan Management Company Quincy, Massachusetts $58.9M AUM 18.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
G
Gainplan Bloomfield Hills, Michigan $254M AUM 25.62% 1-Year Est. Return

Bellevue Group's LABU Position: Q2 2020 in Review

Bellevue Group sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q2 2020, closing a stake of 750 shares — an estimated $338K sold.

Bellevue Group first reported a position in LABU in Q1 2016 and held it in 6 quarters. The position peaked at $2.99M in Q4 2017. 20 funds tracked by Wall St. Rank hold LABU as of Q2 2020.

  • Bellevue Group reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q2 2020 after selling out during the quarter.
  • Bellevue Group sold 750 Direxion Daily S&P Biotech Bull 3X ETF shares in Q2 2020, an estimated $338K.
  • Bellevue Group first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q1 2016 and held it in 6 quarters.
  • Bellevue Group's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $2.99M in Q4 2017.
  • 20 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q2 2020.

Based on Bellevue Group's 13F filing for Q2 2020, filed 13 Aug 2020.